RADIATION THERAPY ONCOLOGY GROUP

罗切斯特大学(UR)的调查人员继续发挥主要作用 在国家一级RTOG协议的设计和开发中的作用 以及为RTOG临床的病例添加和实施做出贡献 所有级别的试验：第一阶段、第二阶段、第三阶段和癌症控制 研究。研究战略副主席和主席的办公室 礼宾委员会的两个分支机构都设在辐射司 罗切斯特大学癌症中心(URCC)肿瘤学(DRO)。这 促进RTOG设计活动的发展和顺利进行 将这些想法结合到工作方案中，允许 排定研究的优先顺序。这些目标是通过两个方面实现的 时尚。首先，将研究作为主要研究主题进行综述。 包括定时剂量和分级时间表、超分割、 放射增敏剂、辐射防护剂、大野和半身照射、 高LET照射，最佳放射治疗和化疗时机， 热疗和其他创新的放射治疗方法 数学建模。其次，对不同解剖部位进行评价。 以确定哪一种最适合具体的研究。这些 包括脑胶质瘤、头颈癌、肺癌、前列腺癌 癌症、结直肠癌、妇科肿瘤和血液病 恶性肿瘤。UR的调查人员对半身人特别感兴趣 放射治疗隐匿性转移瘤。超分割正在兴起 作为许多网站和UR的领先研究概念 研究人员正在积极地将这两个概念结合在一起，形成独特的 创新研究。另一个特别感兴趣的领域是使用 我们在辐射防护剂和辐射增敏剂方面的独特研究 实验室支持系统起着至关重要的作用。半身概念的使用 辐射防护剂和辐射增敏剂已经在我们的 目前正在接受测试。其他感兴趣的领域 包括结直肠癌和前列腺癌，这是UR建议的领域 最近的研究，以及辐射毒理学和病理学和 重新设计治疗恶性血液病的方案。UR一直是一个 案例的主要贡献者和RTOG信誉良好的资助成员 自十年前成立以来。

The University of Rochester (UR) investigators continue to play a major role in the design and development of RTOG protocols on the national level as well as contributing to the case accession and conduct of RTOG Clinical Trials at all levels: Phase I, Phase II, Phase III and Cancer Control Studies. The offices of Vice Chairman for Research Strategies and Chairman of the Protocol Committee are both located within the Division of Radiation Oncology (DRO) at the University of Rochester Cancer Center (URCC). This facilitates development of the design activities of the RTOG and smooth incorporation of these ideas into working protocols, allowing for prioritizing of studies. These ends are accomplished in a two-fold fashion. Firstly, studies are reviewed as major research themes which include time dose and fractionation schedules, hyperfractionation, radiosensitizers, radioprotectors, large field and hemi-body irradiation, high LET irradiation, optimal timing of radiation therapy and chemotherapy, hyperthermia and other innovative approaches in radiation therapy with mathematical modeling. Secondly, different anatomical sites are evaluated to determine which is best suited for specific research studies. These include brain gliomas, head and neck cancers, lung cancers, prostate cancer, colo-rectal cancers, gynecologic tumors and hematologic malignancies. The UR investigators are particularly interested in hemibody irradiation for treating occult metastases. Hyperfractionation is emerging as the leading research concept in a number of sites and the UR investigators are actively combining these two concepts in unique and innovative studies. Another area of particular interest is the use of radioprotectors and radiosensitizers in which our unique research laboratory support system plays a vital role. Use of the hemi-body concept with the radioprotectors and radiosensitizers has been developed at our institution and is currently being tested. Additional areas of interest include colorectal and prostate cancer, areas which the UR has proposed studies recently, as well as radiation toxicology and pathology and redesigning protocols for hematologic malignancies. The UR has been a major contributor of cases and a funded member in good standing of the RTOG since its inception a decade ago.